06 August 2020 | News
The company will provide attractive payment terms for clients choosing to use this cell line technology for their future development
Image credit- prnasia
South Korean firm Samsung Biologics held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice.
S-CHOice builds on glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line technology and shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies. The cell line also shows enhanced cell viability with over 90% at day-21 in a fed-batch study, demonstrating effectiveness in producing high quality cell lines.
Moreover, S-CHOice has a speedy cell division of 18-20 hours and together with Berkeley Lights Beacon® technology, Samsung Biologics can offer reduced development timeline by a month from the industry average of four to five months.
The company will also provide attractive payment terms for clients choosing to use this cell line technology for their future development.
Leveraging these combination of advantages, Samsung Biologics recently signed a development contract with a client under which S-CHOice will be used to advance its cell line development.